View Item 

Show simple item record

RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106

dc.contributor.authorChen, Robert W.
dc.contributor.authorLi, Hongli
dc.contributor.authorBernstein, Steven H.
dc.contributor.authorKahwash, Samir
dc.contributor.authorRimsza, Lisa M.
dc.contributor.authorForman, Stephen J.
dc.contributor.authorConstine, Louis
dc.contributor.authorShea, Thomas C.
dc.contributor.authorCashen, Amanda F.
dc.contributor.authorBlum, Kristie A.
dc.contributor.authorFenske, Timothy S.
dc.contributor.authorBarr, Paul M.
dc.contributor.authorPhillips, Tycel
dc.contributor.authorLeblanc, Michael
dc.contributor.authorFisher, Richard I.
dc.contributor.authorCheson, Bruce D.
dc.contributor.authorSmith, Sonali M.
dc.contributor.authorFaham, Malek
dc.contributor.authorWilkins, Jennifer
dc.contributor.authorLeonard, John P.
dc.contributor.authorKahl, Brad S.
dc.contributor.authorFriedberg, Jonathan W.
dc.date.accessioned2017-04-13T20:35:09Z
dc.date.available2018-05-15T21:02:50Zen
dc.date.issued2017-03
dc.identifier.citationChen, Robert W.; Li, Hongli; Bernstein, Steven H.; Kahwash, Samir; Rimsza, Lisa M.; Forman, Stephen J.; Constine, Louis; Shea, Thomas C.; Cashen, Amanda F.; Blum, Kristie A.; Fenske, Timothy S.; Barr, Paul M.; Phillips, Tycel; Leblanc, Michael; Fisher, Richard I.; Cheson, Bruce D.; Smith, Sonali M.; Faham, Malek; Wilkins, Jennifer; Leonard, John P.; Kahl, Brad S.; Friedberg, Jonathan W. (2017). "RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106." British Journal of Haematology 176(5): 759-769.
dc.identifier.issn0007-1048
dc.identifier.issn1365-2141
dc.identifier.urihttps://hdl.handle.net/2027.42/136294
dc.publisherWiley Periodicals, Inc.
dc.subject.othermantle cell
dc.subject.otherbendamustine
dc.subject.otherAuto‐HCT
dc.subject.otherMRD
dc.subject.otherhyperCVAD
dc.titleRB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136294/1/bjh14480_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136294/2/bjh14480.pdf
dc.identifier.doi10.1111/bjh.14480
dc.identifier.sourceBritish Journal of Haematology
dc.identifier.citedreferenceCheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. ( 2007 ) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579 – 586.
dc.identifier.citedreferenceBernstein, S.H., Epner, E., Unger, J.M., LeBlanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T.P. & Fisher, R.I. ( 2013 ) A phase II multicenter trial of hyperCVAD MTX/Ara‐C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Annals of Oncology, 24, 1587 – 1593.
dc.identifier.citedreferenceFisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O’Connor, O.A., Shi, H.L., Boral, A.L. & Goy, A. ( 2006 ) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 – 4874.
dc.identifier.citedreferenceFaham, M., Zheng, J., Moorhead, M., Carlton, V.E., Stow, P., Coustan‐Smith, E., Pui, C.H. & Campana, D. ( 2012 ) Deep‐sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood, 120, 5173 – 5180.
dc.identifier.citedreferenceDreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C., Schmits, R., Metzner, B., Truemper, L., Reiser, M., Steinhauer, H., Boiron, J.M., Boogaerts, M.A., Aldaoud, A., Silingardi, V., Kluin‐Nelemans, H.C., Hasford, J., Parwaresch, R., Unterhalt, M. & Hiddemann, W. ( 2005 ) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression‐free survival in mantle‐cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 2677 – 2684.
dc.identifier.citedreferenceChopra, R., McMillan, A.K., Linch, D.C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K.G. & Goldstone, A.H. ( 1993 ) The place of high‐dose BEAM therapy and autologous bone marrow transplantation in poor‐risk hodgkin’s disease. A single‐center 8‐year study of 155 patients. Blood, 81, 1137 – 1145.
dc.identifier.citedreferenceBottcher, S., Ritgen, M., Buske, S., Gesk, S., Klapper, W., Hoster, E., Hiddemann, W., Unterhalt, M., Dreyling, M., Siebert, R., Kneba, M. & Pott, C. ( 2008 ) Minimal residual disease detection in mantle cell lymphoma: methods and significance of four‐color flow cytometry compared to consensus IGH‐polymerase chain reaction at initial staging and for follow‐up examinations. Haematologica, 93, 551 – 559.
dc.identifier.citedreferenceZinzani, P.L., Vose, J.M., Czuczman, M.S., Reeder, C.B., Haioun, C., Polikoff, J., Tilly, H., Zhang, L., Prandi, K., Li, J. & Witzig, T.E. ( 2013 ) Long‐term follow‐up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL‐003 study. Annals of Oncology, 24, 2892 – 2897.
dc.identifier.citedreferenceWang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., Romaguera, J.E., Williams, M.E., Barrientos, J.C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., Spurgeon, S.E., Li, L., Zhang, L., Newberry, K., Ou, Z.S., Cheng, N., Fang, B.L., McGreivy, J., Clow, F., Buggy, J.J., Chang, B.Y., Beaupre, D.M., Kunkel, L.A. & Blum, K.A. ( 2013 ) Targeting BTK with ibrutinib in relapsed or refractory mantle‐cell lymphoma. New England Journal of Medicine, 369, 507 – 516.
dc.identifier.citedreferenceTill, B.G., Li, H., Bernstein, S.H., Fisher, R.I., Burack, W.R., Rimsza, L.M., Floyd, J.D., DaSilva, M.A., Moore, D.F. Jr, Pozdnyakova, O., Smith, S.M., LeBlanc, M. & Friedberg, J.W. ( 2016 ) Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. British Journal of Haematology, 172, 208 – 218.
dc.identifier.citedreferenceTill, B.G., Gooley, T.A., Crawford, N., Gopal, A.K., Maloney, D.G., Petersdorf, S.H., Pagel, J.M., Holmberg, L., Bensinger, W. & Press, O.W. ( 2008 ) Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leukemia and Lymphoma, 49, 1062 – 1073.
dc.identifier.citedreferenceThe Non Hodgkin’s Lymphoma Classification Project. ( 1997 ) A clinical evaluation of the International Lymphoma Study Group classification of non‐Hodgkin’s lymphoma. Blood, 89, 3909 – 3918.
dc.identifier.citedreferenceRummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grunhagen, U., Losem, C., Kofahl‐Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Durk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A. & Brugger, W. ( 2013 ) Bendamustine plus rituximab versus CHOP plus rituximab as first‐line treatment for patients with indolent and mantle‐cell lymphomas: an open‐label, multicentre, randomised, phase 3 non‐inferiority trial. Lancet, 381, 1203 – 1210.
dc.identifier.citedreferenceRummel, M.J., Al‐Batran, S.E., Kim, S.Z., Welslau, M., Hecker, R., Kofahl‐Krause, D., Josten, K.M., Durk, H., Rost, A., Neise, M., von Grunhagen, U., Chow, K.U., Hansmann, M.L., Hoelzer, D. & Mitrou, P.S. ( 2005 ) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low‐grade non‐Hodgkin’s lymphoma. Journal of Clinical Oncology, 23, 3383 – 3389.
dc.identifier.citedreferenceRuan, J., Martin, P., Shah, B., Schuster, S.J., Smith, S.M., Furman, R.R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., Katz, O., Coleman, M. & Leonard, J.P. ( 2015 ) Lenalidomide plus rituximab as initial treatment for mantle‐cell lymphoma. New England Journal of Medicine, 373, 1835 – 1844.
dc.identifier.citedreferenceRomaguera, J.E., Fayad, L., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A.H., Dang, N.H., Wang, M., Beasley, V., Medeiros, L.J., Katz, R.L., Gagneja, H., Samuels, B.I., Smith, T.L. & Cabanillas, F.F. ( 2005 ) High rate of durable remissions after treatment of newly diagnosed aggressive mantle‐cell lymphoma with rituximab plus hyper‐CVAD alternating with rituximab plus high‐dose methotrexate and cytarabine. Journal of Clinical Oncology, 23, 7013 – 7023.
dc.identifier.citedreferenceReece, D.E., Connors, J.M., Spinelli, J.J., Barnett, M.J., Fairey, R.N., Klingemann, H.G., Nantel, S.H., O’Reilly, S., Shepherd, J.D. & Sutherland, H.J. ( 1994 ) Intensive therapy with cyclophosphamide, carmustine, etoposide +/− cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood, 83, 1193 – 1199.
dc.identifier.citedreferencePott, C., Hoster, E., Delfau‐Larue, M.H., Beldjord, K., Bottcher, S., Asnafi, V., Plonquet, A., Siebert, R., Callet‐Bauchu, E., Andersen, N., van Dongen, J.J., Klapper, W., Berger, F., Ribrag, V., van Hoof, A.L., Trneny, M., Walewski, J., Dreger, P., Unterhalt, M., Hiddemann, W., Kneba, M., Kluin‐Nelemans, H.C., Hermine, O., Macintyre, E. & Dreyling, M. ( 2010 ) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood, 115, 3215 – 3223.
dc.identifier.citedreferencePott, C. ( 2011 ) Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. Seminars in Hematology, 48, 172 – 184.
dc.identifier.citedreferenceNademanee, A., O’Donnell, M.R., Snyder, D.S., Schmidt, G.M., Parker, P.M., Stein, A.S., Smith, E.P., Molina, A., Stepan, D.E. & Somlo, G. ( 1995 ) High‐dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory hodgkin’s disease: results in 85 patients with analysis of prognos. Blood, 85, 1381 – 1390.
dc.identifier.citedreferenceLiu, H., Johnson, J.L., Koval, G., Malnassy, G., Sher, D., Damon, L.E., Hsi, E.D., Bucci, D.M., Linker, C.A., Cheson, B.D. & Stock, W. ( 2012 ) Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica, 97, 579 – 585.
dc.identifier.citedreferenceKaplan, G. & Meier, P. ( 1958 ) Non‐parametric estimations from incomplete observations. Journal of American Statistical Association, 53, 457 – 481.
dc.identifier.citedreferenceHoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin‐Nelemans, H.C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., Peter, N., Jung, W., Wörmann, B., Ludwig, W.‐D., Dührsen, U., Eimermacher, H., Wandt, H., Hasford, J., Hiddemann, W. & Unterhalt, M. ( 2008 ) A new prognostic index (MIPI) for patients with advanced‐stage mantle cell lymphoma. Blood, 111, 558 – 565.
dc.identifier.citedreferenceHerrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wormann, B., Trumper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M. & Dreyling, M. ( 2009 ) Improvement of overall survival in advanced stage mantle cell lymphoma. Journal of Clinical Oncology, 27, 511 – 518.
dc.identifier.citedreferenceHermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., Szymczyk, M., Bouabdallah, R., Kneba, M., Hallek, M., Salles, G., Feugier, P., Ribrag, V., Birkmann, J., Forstpointner, R., Haioun, C., Hanel, M., Casasnovas, R.O., Finke, J., Peter, N., Bouabdallah, K., Sebban, C., Fischer, T., Duhrsen, U., Metzner, B., Maschmeyer, G., Kanz, L., Schmidt, C., Delarue, R., Brousse, N., Klapper, W., Macintyre, E., Delfau‐Larue, M.H., Pott, C., Hiddemann, W., Unterhalt, M. & Dreyling, M. ( 2016 ) Addition of high‐dose cytarabine to immunochemotherapy before autologous stem‐cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open‐label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, 388, 565 – 575.
dc.identifier.citedreferenceGeisler, C.H., Kolstad, A., Laurell, A., Jerkeman, M., Raty, R., Andersen, N.S., Pedersen, L.B., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G.F., Nilsson‐Ehle, H., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen‐Lindsberg, M.L., Brown, P. & Elonen, E. ( 2012 ) Nordic MCL2 trial update: 6‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur. British Journal of Haematology, 158, 355 – 362.
dc.identifier.citedreferenceGeisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A.M., Kuittinen, O., Lauritzsen, G.F., Nilsson‐Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundstrom, C., Langholm, R., Delabie, J., Karjalainen‐Lindsberg, M.L., Brown, P. & Elonen, E. ( 2008 ) Long‐term progression‐free survival of mantle cell lymphoma after intensive front‐line immunochemotherapy with in vivo‐purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112, 2687 – 2693.
dc.identifier.citedreferenceFlinn, I.W., van der Jagt, R., Kahl, B.S., Wood, P., Hawkins, T.E., Macdonald, D., Hertzberg, M., Kwan, Y.L., Simpson, D., Craig, M., Kolibaba, K., Issa, S., Clementi, R., Hallman, D.M., Munteanu, M., Chen, L. & Burke, J.M. ( 2014 ) Randomized trial of bendamustine‐rituximab or R‐CHOP/R‐CVP in first‐line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 123, 2944 – 2952.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh14480_am.pdf
Size:
266.6KB
Format:
PDF
View/Open
Name:
bjh14480.pdf
Size:
215.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.